Innovent's Metabolic Pipeline Data Stands Out; Oral GLP-1 Shows Significant Early Weight Loss Effect

Overview

This report interprets Innovent Biologics' latest metabolic pipeline data presented at the 2026 American Diabetes Association (ADA) meeting. Core focus is on the early weight loss efficacy of oral GLP-1 candidate IBI3032, results from two Chinese Phase III clinical trials for mazdutide, and progress on three preclinical assets. Goldman Sachs views the data as generally positive, supporting enhanced competitiveness in the metabolic sector, maintains a Buy rating with a target price of HK$107.04.

Core views

Oral GLP-1 candidate IBI3032 demonstrates differentiation potential. The Phase I multiple ascending dose (MAD) study showed that the 9mg dose group achieved placebo-adjusted average weight loss of -8.6% at week 4 (-10.7% vs. placebo -2.1%), outperforming comparable oral GLP-1 data at 28-day cutoff points (e.g., Ascletis ASC30 -6.2%, Roche CT-996 -6.1%). Via a 7-step dose escalation protocol, vomiting incidence was controlled at 8.3%, showing significant tolerance improvement and providing dosing regimen reference for subsequent studies. However, development progress still lags behind certain competitors (e.g., aleniglipron approx. 2.5 years, ASC30 approx. 1.5 years); global clinical execution capability remains a key observation point. Mazdutide efficacy exceeds semaglutide. Two Chinese Phase III studies (GLORY-2/DREAMS-3) showed that the 9mg dose achieved placebo-adjusted weight loss of -15.53% over 60 weeks in obese patients with BMI≥30 (-18.55% vs. placebo -3.02%), rising further to -17.3% in non-T2D patients, surpassing semaglutide (-12.6% at 104 weeks) and approaching tirzepatide (-20.1% at 72 weeks). In a head-to-head trial for T2D patients with obesity, 6mg mazdutide reduced HbA1c by -2.03% and weight by -10.3% over 32 weeks, outperforming 1mg semaglutide (-1.84%, -6%), while doubling the proportion of patients achieving both HbA1c<7.0% and weight loss≥10% (48% vs. 21%). However, gastrointestinal adverse event rates were higher than those for tirzepatide and semaglutide. Preclinical pipeline expansion bolsters long-term competitiveness. IBI3042 is a potential first-in-class once-weekly oral GLP-1; efficacy in monkey models matches daily orforglipron, expected to enter human trials by end of 2026; IBI3040 (amylin/CTR receptor agonist) shows synergistic potential with GLP-1 drugs in mouse models; IBI3046 (INHBE siRNA) offers quarterly or semiannual dosing long-acting capabilities.

Analysis framework

Goldman Sachs employed a DCF valuation model, setting a discount rate of 10% and a terminal growth rate of 3%, resulting in a 12-month target price of HK$107.04. The analysis logic centers on pipeline data competitiveness: horizontal comparison of similar drugs' early weight loss curves and tolerance data to assess IBI3032's differentiation potential; verification of mazdutide's efficacy advantage over semaglutide through Phase III head-to-head trial results; and judgment of long-term pipeline depth combined with preclinical asset progress. Additionally, attention is paid to commercialization capabilities (e.g., rapid sales ramp-up of sintilimab) and global partnerships (particularly with Eli Lilly) in supporting valuation.

Methodology notes

• Valuation MethodDCF Cash Flow Discount

  DCF Cash Flow Discount Model

  Calculates enterprise intrinsic value by projecting future free cash flows and discounting them to present value using a specific discount rate, plus terminal value. This report sets a 10% discount rate and 3% terminal growth rate, reflecting a comprehensive assessment of Innovent Biologics' pipeline monetization capabilities and risks.

• Industry/Industrial Analysis FrameworkSupply-demand framework

  Metabolic Drug Market Competition Landscape Analysis

  Assesses Innovent Biologics' competitive position in the GLP-1 track by comparing efficacy, tolerance, and development progress of similar drugs. For example, comparing IBI3032 early weight loss data with competitors like Ascletis, Roche, and Hengrui to judge differentiation advantages and catch-up space.

• Company Fundamentals and Financial FrameworkProfitability Quality Analysis

  Pipeline Value and Commercialization Capability Assessment

  Combines commercialized product sales speed (e.g., sintilimab) with R&D pipeline clinical data to judge income sustainability and valuation reasonableness. The report believes current share prices do not fully reflect strong revenue and pipeline value.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Innovent Biologics (1801.HK)

  Beneficiary; core metabolic pipeline data positively supports valuation

  Strengths

  Mazdutide efficacy exceeds semaglutide; differentiated early data for oral GLP-1; strong commercialization capabilities

  Weaknesses

  Oral GLP-1 R&D progress lags competitors by approx. 1.5-2.5 years; GI tolerance requires optimization

  Comparison

  Compared to oral GLP-1 competitors like Hengrui and Roche, early weight loss data is superior but development progress lags

  Risks

  Intensifying PD-1 market competition; delay in key candidate approvals; R&D failure risks

Key data

• IBI3032 9mg dose 4-week weight loss-8.6% (placebo-adjusted)Outperforms similar oral GLP-1 data at 28-day cutoff
• Mazdutide 9mg 60-week weight loss-15.53% (placebo-adjusted)Patients with BMI≥30, outperforms semaglutide
• Mazdutide vs. Semaglutide head-to-headHbA1c -2.03% vs. -1.84%T2D patients with obesity at 32 weeks; weight loss -10.3% vs. -6%
• Target PriceHK$107.04Based on DCF model, implies 44% upside
• Current Share PriceHK$74.35Closing price as of June 10, 2026

Impact & implications

The report posits that positive data will help Innovent Biologics establish competitiveness in the metabolic drug sector. Timely approval of the 9mg mazdutide dose could expand patient coverage, capturing market share before semaglutide generics enter the Chinese market. If subsequent clinical execution of oral GLP-1 proceeds smoothly, it may offset the disadvantage of lagging R&D progress. Long-term, successful advancement of preclinical assets (such as once-weekly oral GLP-1 and long-acting siRNA) would enhance platform value. However, risks include intensifying PD-1 market competition, uncertainty in key candidate approvals, limitations on off-label use due to safety issues, and R&D failure risks.

Risks

• Intensifying competition in China's PD-1/L1 market
• Uncertainty regarding timing of key candidate approvals
• Safety issues leading to limitations on off-label use
• Risk of project failure

What to watch

• Progress of subsequent global clinical execution for IBI3032
• Approval timeline for mazdutide 9mg dose
• Timing of semaglutide generic entry into the Chinese market
• Initiation of human trials for preclinical assets IBI3042/3040/3046